2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

1937 Outcomes of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) achieving initial partial response or stable disease to CD3xCD20 bispecific antibodies and the impact of time to complete response: A multicenter retrospective study

Yazeed Sawalha, MD, Subodh Bhatta, PhD2, Sonia Godbole, MD3, Jarrod Smith, MD4, Shakthi P. Bhaskar, MD5, Andrew P. Jallouk, MD, PhD6, Lorenzo Falchi, MD7, Ayushi Chauhan, MD8, Swetha Thiruvengadam, MD9, Reid W Merryman, MD10, Ajay Major, MD, MBA11, Allison Marie Bock, MD12, Matthew A. Lunning, DO, FACP13, Gulrayz Ahmed, MD14, Amy A. Ayers15, Mehdi Hamadani, MD16, Narendranath Epperla, MD, MS, FACP17, Steven Bair, MD18, Geoffrey Shouse, DO PhD19, Alex Francisco Herrera, MD20, Alexey V. Danilov, MD, PhD21, Christopher R. Flowers Jr, MD, MS22, Gilles Salles I, MD, PhD23, Sairah Ahmed, MD24, Jennifer L. Crombie, MD25
1 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 Vanderbilt University, Nashville, United States
5 Vanderbilt University, Nashville, United States
6 Vanderbilt University, Nashville, United States
7 Memorial Sloan Kettering Cancer Center, New York City, United States
8 MD Anderson Cancer Center, Houston, United States
9 City of Hope National Medical Center, Duarte, United States
10 Dana-Farber Cancer Institute, Boston, United States
11 University of Colorado School of Medicine, Denver, United States
12 Huntsman Cancer Institute, University of Utah, Salt Lake City, United States
13 University of Nebraska Medical Center, Omaha, United States
14 Medical College of Wisconsin, Milwaukee, United States
15 The University of Texas MD Anderson Cancer Center, Houston, United States
16 Medical College of Wisconsin, Milwaukee, United States
17 Huntsman Cancer Institute, University of Utah, Salt Lake City, United States
18 University of Colorado School of Medicine, Denver, United States
19 City of Hope National Medical Center, Duarte, United States
20 City of Hope National Medical Center, Duarte, United States
21 City of Hope National Medical Center, Duarte, United States
22 MD Anderson Cancer Center, Houston, United States
23 Memorial Sloan Kettering Cancer Center, New York City, United States
24 MD Anderson Cancer Center, Houston, United States
25 Dana-Farber Cancer Institute, Boston, United States

Background: Complete responses (CRs) to CD3xCD20 bispecific antibodies (BsAbs) in R/R LBCL are typically observed early. However, a subset of patients (pts) achieve an initial partial response (PR) or stable disease (SD), and data on their clinical course are limited. We evaluated outcomes of pts with initial PR/SD (iPR/SD), focusing on CR conversion rates and the impact of time to CR on outcomes.

Methods: This is a multicenter retrospective study of pts with R/R LBCL treated with commercial CD3xCD20 BsAbs across 10 US centers within the Collaborative US Bispecific Consortium (CUBIC). Timing of first response assessment (FRA) and response assessment (RA) intervals were at treating physician discretion, with responses evaluated locally per Lugano criteria. To assess if the time to achieveing first CR affects response durability, we compared duration of CR (DoCR; first CR to progression (PD) or death) categorically (initial CR [iCR] vs subsequent [subCR]) and by modeling time to CR as a continuous variable, estimating the hazard ratio (HR) for PD or death per 1-month increase in time to CR. iCR was CR at FRA, and subCR was CR at subsequent RA. Progression-free survival (PFS) and overall survival (OS) were calculated from BsAb initiation.

Results: Among 520 pts, histology was diffuse large B-cell lymphoma (DLBCL) (84%) and high-grade B-cell lymphoma (HGBCL) (14%) (others=2%). BsAb was glofitamab (54%), epcoritamab (41%), or mosunetuzumab (5%), given as monotherapy (48%), or with systemic therapy (48%), or radiation (4%). Median number of prior lines of therapy (pLOT) was 3; 47% had prior CAR T. First response was CR in 121 (28%) pts (iCR cohort), PR in 118 (27%), SD in 17 (4%), and PD in 178 (41%), and missing in 86 (17%; of those, 51 (59%) died or stopped BsAb within 60 days). PET/CT was used for FRA in 229/256 (90%) of pts with CR/PR/SD. The 1-year PFS and OS rates for the overall cohort were 33% and 45%.

Of 135 pts with iPR/SD, median age was 69 (range 22-91); 86 (64%) were male; 24 (20%) had performance status ≥2; 106 (87%) stage III/IV; 109 (85%) extranodal (EN) disease; 19 (17%) bulky disease (≥7 cm); 92 (69%) elevated LDH; 72 (67%) IPI ≥3. Histology was DLBCL (n=112, 83%), HGBCL (n=21, 16%), and others (n=2, 1%). FRA was by PET/CT in 119 pts (88%), with median time to FRA of 1.8 months (interquartile range [IQR] 1.4-2.4). BsAb was glofitamab (n=82, 61%), epcoritamab (n=51, 38%), or mosunetuzumab (n=2, 1%), as monotherapy (n=59, 44%), combination systemic therapy (n=72, 53%), or with radiation (n=4, 3%). Median number of pLOT was 3 (range 1–16); 49% had prior CAR T.

Of pts with iPR/SD: 46 (34%) converted to CR (subCR cohort) (PR: 43/118, 36%; SD: 3/17, 18%) after a median of 4.8 months (IQR 2.9-6.1), 7 (5%) remained PR/SD and 59 (44%) had PD without CR after a median of 2 months (IQR 1.6-3.0). Others stopped for toxicity (n=5, 4%), transitioned to CAR T (n=10, 7%), or remained on therapy (n=4, 3%) (missing, n=4). At 1.3-year median follow-up, 1-year PFS and OS for iPR/SD were 43.5% (95% CI: 35.6–53.1) and 69.0% (95% CI: 61.0–78.1). Compared with iCR, iPR/SD had inferior PFS (HR 2.7, 95% CI: 1.8–4.0, p<.0001) and OS (HR 2.1, 95% CI: 1.3–3.4, p=.003). 1-year PFS and OS for initial SD vs PR were 33.6% and 47.5% vs 44.9% and 71.8% (HRs for PFS: 1.6, 95%CI: 0.87-2.96, p=.132, and for OS: 1.87, 95%CI: 0.91-3.85, p=.089). Univariable analysis did not identify any baseline or treatment factors predicting conversion to CR.

Median time to iCR was 2.2 months (IQR 1.6–3.2) vs 6.7 months (IQR 5.2-9.7) for subCR. At 0.9-year median follow-up from CR, 1-year DoCR was similar for iCR (68.3%, 95% CI: 59.5-78.5) vs subCR (70.4%, 95% CI: 55.2-89.7; HR 0.78, p=.49). When analyzed as a continuous variable, time to first CR was not significantly associated with DoCR (HR 0.90 per month increase, 95% CI: 0.80–1.03, p=.115). DoCR for iCR vs subCR was similar in pts treated with BsAb monotherapy (HR 0.71, 95% CI: 0.28–1.79, p=.464) or combination (HR 1.00, 95% CI: 0.33–2.98, p=.996).

Conclusions: About one-third of pts with R/R LBCL with iPR/SD on CD3xCD20 BsAbs convert to CR. Although pts with iPR/SD had inferior PFS and OS overall, those converting to CR achieve outcomes comparable to initial CR, with no clinical impact of CR timing whether analyzed categorically or as a continuous variable. Additional studies are required to identify predictors of conversion from PR/SD to CR.

Yazeed Sawalha, MD: BeOne - Research Funding; AbbVie - Research Funding; Genmab - Research Funding; BeOne - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); ADC - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)